Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone
Drug ID BADD_D00623
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage Dexamethasone and [ciprofloxacin] otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa.[L10698] Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Oral tablets are indicated for the treatment of multiple myeloma.[L10710] An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye.[L10719] Various ophthalmic formulations are indicated for inflammatory conditions of the eye.[L10704,L10707,L10713,L10716,L10722,L10725]
Marketing Status approved; investigational; vet_approved
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D00292
MeSH ID D003907
PubChem ID 5743
TTD Drug ID D0IT2G
NDC Product Code 80425-0328; 0009-5019; 22552-0039; 38779-0405; 0904-7266; 55154-4901; 63187-561; 67296-1496; 70518-2998; 70868-920; 0054-4183; 0054-8176; 0054-8181; 0054-8183; 0998-0615; 55718-133; 71161-138; 79572-012; 42195-490; 45865-989; 55154-4914; 68788-8223; 70382-204; 71205-012; 42291-155; 50090-0088; 60687-718; 60687-729; 64980-509; 68788-8467; 72189-383; 55289-582; 60219-2044; 67296-0326; 0054-4179; 0054-8179; 0054-8180; 72893-015; 55718-157; 65089-0045; 42195-127; 60219-2043; 63629-7850; 70954-402; 71205-013; 0054-4181; 0054-4182; 0054-4186; 71205-703; 71879-001; 46439-8765; 82298-111; 50090-6151; 61919-827; 63187-383; 63629-4129; 63629-7806; 68788-7267; 69306-111; 69306-114; 70518-3050; 70954-404; 0054-4184; 49452-2465; 0078-0925; 0023-3348; 61919-269; 68071-2744; 68788-8293; 0054-3177; 70954-403; 0054-8175; 71335-2108; 72189-254; 51552-0430; 51927-1081; 52128-170; 42195-721; 43063-266; 48102-051; 50090-0089; 54879-003; 60219-2056; 62135-114; 68788-7142; 70954-401; 0054-8174; 72189-468; 60722-3013; 0121-1814; 42195-121; 42195-149; 42195-221; 47781-914; 47781-916; 55700-961; 69306-112; 55289-903; 63629-3742; 66993-730; 67296-1837; 68071-2321; 0054-4180; 55718-156; 57582-031; 57582-931; 42195-270; 50090-6152; 51407-361
UNII 7S5I7G3JQL
Synonyms Dexamethasone | Methylfluorprednisolone | Hexadecadrol | Decameth | Decaspray | Dexasone | Dexpak | Maxidex | Millicorten | Oradexon | Decaject | Decaject-L.A. | Decaject L.A. | Hexadrol
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 50-02-2
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebral haematoma17.08.01.014; 24.07.04.0060.000218%Not Available
Dacryostenosis acquired06.06.04.0030.000218%Not Available
Vessel puncture site haemorrhage12.07.04.014; 08.02.04.014; 24.07.01.0610.000145%Not Available
Affect lability19.04.01.001--Not Available
Corneal thinning06.06.03.0090.000218%Not Available
Scleral thinning06.09.06.004--Not Available
Anterior chamber inflammation06.04.10.0020.000218%Not Available
Haemorrhoidal haemorrhage24.10.02.001; 07.15.03.0020.000145%
Genital burning sensation21.10.01.0050.000145%Not Available
Cerebral disorder17.02.10.0170.000218%Not Available
Foetal death08.04.01.011; 18.01.02.0030.000727%
Haemorrhage24.07.01.002--Not Available
Faecaloma07.01.03.0040.000291%Not Available
Pulmonary mass22.02.07.0040.000218%Not Available
Peripheral sensorimotor neuropathy17.09.03.0090.000145%Not Available
Gaze palsy17.02.05.044; 06.05.02.0140.000145%Not Available
Muscle mass15.05.03.018--Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000538%Not Available
Pupillary deformity06.05.03.0110.003022%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.001380%
Major depression19.15.01.0030.000145%Not Available
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.000291%Not Available
Cancer pain16.32.03.0040.000145%Not Available
Pulseless electrical activity02.03.04.0200.000145%Not Available
Cystoid macular oedema12.02.02.005; 06.04.06.0100.000654%Not Available
Dysgraphia17.02.03.0060.000145%Not Available
Ventricular dysfunction02.04.02.0050.000145%Not Available
Angiopathy24.03.02.0070.000145%Not Available
Metastases to central nervous system16.22.02.004; 17.02.10.0130.000654%Not Available
Secondary hypogonadism21.16.01.001; 05.03.04.0080.000145%Not Available
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene